HitGen And Aduro Biotech Enter Research Collaboration

CHENGDU, China--(BUSINESS WIRE)--HitGen Ltd announced that the company has entered into a multi-target multi-year collaboration with Aduro Biotech Inc , to discover novel small molecule leads for multiple therapeutic targets of interest to Aduro. According to the agreement, HitGen will use its advanced technology platform, based on DNA-encoded library (DEL) design, synthesis and screening to discover novel leads which will be licensed exclusively to Aduro. Under the terms of the agreement, HitGen will receive an upfront payment and be eligible for milestone payments from Aduro.

“We are delighted to enter this collaboration with Aduro, one of the leading biotech companies in the immuno oncology field in the world. We will work closely with Aduro scientists to help generate new and more effective therapeutics for patients” said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen.

About HitGen Ltd

HitGen is a biotech company with headquarters and main research facilities based in Chengdu, China and with laboratory in Houston, Texas, USA. HitGen has established a unique platform for drug discovery research. Our DNA encoded chemical libraries (DELs) contain more than 85 billion novel, diverse, drug-like compounds. These compounds are members of DELs synthesised from many hundreds of distinct chemical scaffolds, designed with tractable chemistry and proven results for finding drug leads against targets from known and novel protein classes. HitGen is working with multiple pharmaceutical, biotech companies and research institutes to discover and develop novel therapeutics of the future.